April 25, 2016

MolecularMD has obtained CE Marking of a Diagnostic Assay Developed for a Daiichi Sankyo, Inc. Phase II Clinical Trial

PORTLAND, OR and CAMBRIDGE, MA – April 25, 2016 – MolecularMD Corp., a molecular diagnostics company that accelerates oncology drug development by providing custom companion diagnostic solutions and supporting clinical trial services for targeted cancer therapies, has partnered with Daiichi Sankyo, Inc. on their work in developing oncology compounds. In collaboration with Daiichi Sankyo, MolecularMD has validated a clinical trial assay that will be used to enrich the patient population for a Phase II clinical trial which is commencing in Europe. MolecularMD has completed the CE registration with the European authorities to ensure future access as an assay, which is to be used for patient selection into the trial. “Identifying the precise subset of patients who may respond to our compound helps to fully assess its potential efficacy and safety profile,” said Antoine Yver, MD, MSc, Executive VP and Global Head, Oncology R&D, Daiichi Sankyo. “MolecularMD is entirely focused on accelerating development of precision oncology medicines. Our work with Daiichi Sankyo demonstrates our ability to support a wide spectrum of clinical and regulatory strategies, stated Dan Snyder, CEO of MolecularMD. “We have a long standing and successful collaboration with their team”. The arrangement with Daiichi Sankyo represents just one of MolecularMD’s Master Service Agreements among the top 25 prominent BioPharma companies in the Industry.